Search:

Partnership opportunities

Our technology in action

Patient information

Contact us

Timelines

Clinical Pipeline

1. Lead indication for ThermoDox^® (Primary Liver Cancer)
   • Pivotal Phase III HCC agreed - January 2008; study sites, including China; primary end point is progression-free survival
2. Second indication for ThermoDox (RCW)
   • Phase I enrolling to establish MTD, anticipate this study will establish a safe and useful dose by the third quarter of 2008. Demonstrated biological activity (complete local response) at 30 mg/m² in patient population.
   • Pivotal multi-site RCW trial to be initiated in late 2008.

Complete Product Pipeline